2022 Revenues ($USD) : $4,585,064,000
2022 R&D spend : $87,944,000
2022 Number of Employees : 16,000
Fiscal Year End : 3/31/2022
Company CEO : Daniel Carestio, president and CEO

Steris jumped nearly 10 positions up the Big 100 ranking in 2022 after 2021 brought a new CEO and a big acquisition contributing to top-line sales this year. The sterilization and surgical products company closed on its $4.6 billion purchase of Cantel Medical in June 2021 and replaced Steris CEO Walt Rosebrough with Daniel Carestio the following month. Sales for the full year (through March 2022) increased nearly 40% from fiscal 2021, with year-over-year healthcare revenue growth of 32% year-over-year, applied sterilization technologies growth of 19% and life sciences growth of 15%. “While supply chain and inflation continue to be a challenge, our teams have worked to address these issues with minimal impact on our ability to serve our customers. As we look ahead at the new fiscal year, we expect another record year of performance,” Carestio said while announcing the results. –JH